NCT00528450View on ClinicalTrials.gov

Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Leukemia
Interventions
DRUG

arsenic trioxide

DRUG

idarubicin

DRUG

tretinoin

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Cephalon
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Cephalon

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00528450 - Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | Biotech Hunter | Biotech Hunter